Quad Technologies, a provider of cell and gene therapy bioprocessing reagents, has opened a new, larger headquarters and laboratory in order to expand manufacturing capabilities and offer clients quality reagents for gene-modified cell therapy bioprocesses. 

“We are delivering a service and product that no other company currently offers: a unique T-cell activation reagent using patented QuickGel that ensures optimal efficiency and effectiveness. By moving into this larger office and laboratory space with ISO 8 and ISO 7 clean rooms, we are poised for immediate expansion that benefits the biotechnology industry,” said Quad Technologies co-founder and chief executive officer, Sean Kevlahan. 

According to the company, along with the facility expansion, their staff is expected to grow up to 70 percent over the next year.